Loading...
•
Dec 31, 2021
Centessa Q4 2021 Earnings Report
Centessa Pharmaceuticals' financial results for Q4 2021 were reported, along with a business update that highlights a strengthened strategic focus on rare disease and immuno-oncology assets.
Key Takeaways
Centessa Pharmaceuticals reported cash and cash equivalents of $595.1 million as of December 31, 2021. The company is focusing on rare disease and immuno-oncology assets, with SerpinPC registration studies planned for 2H 2022 and LB101 preclinical data expected at ASCO 2022.
Strategic focus strengthened on rare disease and immuno-oncology assets.
SerpinPC registration studies are planned to begin in the second half of 2022, focusing on Hemophilia B.
LB101 preclinical data is expected to be shared at ASCO 2022, with an IND planned for late 2022.
Cash and cash equivalents totaled $595.1 million as of December 31, 2021.
Centessa
Centessa
Forward Guidance
Centessa Pharmaceuticals is advancing multiple programs towards key milestones, including registrational studies for Lixivaptan and SerpinPC, and IND filings for LB101, LB201, MGX292, CBS004 and OX2R Agonists.
Positive Outlook
- Lixivaptan is currently being administered in the Phase 3 registrational ACTION Study.
- SerpinPC: In the second half of 2022 the Company expects to launch two registrational studies.
- LB101 preclinical data is expected to be shared at ASCO 2022, with an IND for LB101 planned for late 2022.
- ZF874: We expect to share Phase 1 data from multiple dose cohorts with PiMZ and PiZZ subjects in 2H 2022.
- CBS001 in Inflammatory / Fibrotic Diseases: Phase 1 clinical trial in healthy volunteers is expected to begin in the second quarter of 2022.
Challenges Ahead
- Discontinued the small molecule EGFR inhibitor discovery program.
- Evaluating strategic options for imgatuzumab.
- Discontinued internal funding for the lead dual-STAT3/5 degrader program.
- The ACTION Study is expected to enroll ~1,350 subjects across>200 sites in over 20 countries, with completion anticipated in the second half of 2023.
- Registrational plans for Hemophilia A are in development.